Drugs’ Path to China Slows as Regulatory Delays Add Up, J&J Says

The Chinese pharmaceutical market is becoming increasingly challenging for drug companies because of how long regulators there take to approve new medicines, Johnson & Johnson’s Chief Scientific Officer Paul Stoffels said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.